Vectorized Delivery of Alpha-GalactosylCeramide and Tumor Antigen on Filamentous Bacteriophage fd Induces Protective Immunity by Enhancing Tumor-Specific T Cell Response.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed, 25 citations in OpenAlex.

1. Challenges and opportunities on achieving an adequate delivery efficiency and immunogenicity with peptide-based anticancer vaccines.Advanced drug delivery reviews · 2025
   Review
2. A Programmable Nanovaccine Platform Based on M13 Bacteriophage for Personalized Cancer Vaccine and Therapy.Advanced materials (Deerfield Beach, Fla.) · 2025
   Article
3. PEI-Engineered Lipid@PLGA Hybrid Nanoparticles for Multimodal Delivery of Antigens and Immune Adjuvants to the Respiratory Mucosa.Advanced healthcare materials · 2024
   Article
4. Co-Delivery of the Human NY-ESO-1 Tumor-Associated Antigen and Alpha-GalactosylCeramide by Filamentous Bacteriophages Strongly Enhances the Expansion of Tumor-Specific CD8+ T Cells.Viruses · 2023
   Article
5. PLGA microparticle formulations for tunable delivery of a nano-engineered filamentous bacteriophage-based vaccine: in vitro and in silico-supported approach.Journal of nanostructure in chemistry · 2023
   Article
6. HER2-Displaying M13 Bacteriophages induce Therapeutic Immunity against Breast Cancer.Cancers · 2022
   Article
7. Crosstalk between the Intestinal Virome and Other Components of the Microbiota, and Its Effect on Intestinal Mucosal Response and Diseases.Journal of immunology research · 2022
   Review
8. Glycoconjugate Nanoparticle-Based Systems in Cancer Immunotherapy: Novel Designs and Recent Updates.Frontiers in immunology · 2022
   Review
9. Nanocell COVID-19 vaccine triggers a novel immune response pathway producing high-affinity antibodies which neutralize all variants of concern.Frontiers in immunology · 2022
   Article
10. Lipids in Pathophysiology and Development of the Membrane Lipid Therapy: New Bioactive Lipids.Membranes · 2021
    Review
11. Exploiting viral sensing mediated by Toll-like receptors to design innovative vaccines.NPJ vaccines · 2021
    Review
12. Self-assembled peptide and protein nanostructures for anti-cancer therapy: Targeted delivery, stimuli-responsive devices and immunotherapy.Nano today · 2021
    Article
13. Harnessing NKT cells for vaccination.Oxford open immunology · 2021
    Review
14. Advancements in prophylactic and therapeutic nanovaccines.Acta biomaterialia · 2020
    Review
15. Carbohydrate Conjugates in Vaccine Developments.Frontiers in chemistry · 2020
    Review
16. Phage display as a tool for vaccine and immunotherapy development.Bioengineering & translational medicine · 2020
    Review
17. Arming Filamentous Bacteriophage, a Nature-Made Nanoparticle, for New Vaccine and Immunotherapeutic Strategies.Pharmaceutics · 2019
    Review
18. Chlorotoxin targets ERα/VASP signaling pathway to combat breast cancer.Cancer medicine · 2019
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

7 authors at 3 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as